News – Page 1117 – Endpoints News

Slammed by more deaths, Seattle Genetics scraps a PhIII study and pulls back (again) on vadastuximab

8 years ago

Clovis soars as a new round of PhIII Rubraca data looks promising — but roci scandal bites again with $142M ...

8 years ago

EY: Post-boom biotech still has plenty of upbeat trends to boast about

8 years ago

Billionaire-backed Parker Institute tackles the Holy Grail of cancer R&D — with a virtual unknown

8 years ago

Clancy joins the new team at Alexion, investment banker joins Flagship, Deeg quickly rises through ranks at Regulus

8 years ago

Loxo raising $227M in post-ASCO score; Bavarian Nordic reports data delay; Sonar and Stratus ordered to cease ...

8 years ago

Looking to face down major league rivals, Novartis posts some impressive longterm data on Cosentyx

8 years ago

Biotech crossover investor Foresite is lining up a $650M stake for the big gambles to come

8 years ago

From bombs to bromides? Trump’s jousting with biopharma may well boil down to a handshake on drug prices

8 years ago

J&J sets out to build a new R&D group after a $1B biotech christening

8 years ago

Art Krieg comes down from the mountain with a $27M round for Checkmate Pharmaceuticals

8 years ago

The myth of “leaner and meaner” pharma

8 years ago

Alexandria LaunchLabs opens, J&J announces more collaborations

8 years ago

Researchers develop a small-molecule 'sunless tan' to guard against skin cancer

8 years ago

After a sharp plunge, Epizyme bounces back on some bonny forecasts as shares go on a roller coaster ride

8 years ago

Opko insists that ‘outliers’ screwed up its big PhIII study on a Pfizer-partnered therapy

8 years ago

Little Aziyo is growing a new regenerative med company, led by some familiar faces in the biz

8 years ago

Keytruda bonanza inspires a facelift and plans to invest more than $600M in translational research

8 years ago

With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope

8 years ago

Orum takes $8M in Series A; Twist bags $27M in venture financing

8 years ago

Epizyme shares slump as cancer drug data update disappoints

8 years ago

With Kite’s PDUFA date looming, federal court tosses Juno’s CAR-T patent challenge — for now

8 years ago

Aldeyra slides as lead drug flunks a primary endpoint in PhIIb

8 years ago

Jeffrey Kindler’s Centrexion spells out positive data for its PhIII-ready pain drug

8 years ago

First page Previous page 1114 1115 111611171118 1119 1120 Next page Last page